( nnel recently deployed in the Middle Ea...)Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials,Health
| HOME >> MEDICINE >> TECHNOLOGY |
nnel recently deployed in the Middle East, 76% reported at least one episode of diarrhoea and more than 50% reported multiple episodes.
Current travel patterns suggest that in 2020 there will be about 190 million susceptible individuals travelling from significant economies to regions at risk of TD. Under current conditions, 20% - 90% of these individuals would be expected to develop TD within two weeks of arrival. Similar numbers of individuals are likely to visit regions at intermediate risk of TD and about 8 _ 20% of these individuals would be expected to develop TD.
Antibiotics are frequently prescribed to treat infection and anti-diarrhoeal agents are used to treat the symptoms, but at present there is no commercially available vaccine to address Campylobacter jejuni.
ACE BioSciences
ACE BioSciences is an emerging pharmaceutical company focused on developing novel protein-based vaccines and antibodies to address infectious diseases. It has unique expertise in the extraction and analysis of the cell surface proteins used by pathogens (eg bacteria, viruses and fungi) to interact with and infect human host cells. ACE BioSciences aims to develop a portfolio of products independently and in collaboration with other companies. In addition to ACE393, the company is working on a vaccine for Streptococcus pneumoniae, the bacterium responsible for Pneumococcal disease. The market for a Streptococcus product would be multibillion and ACE BioSciences aims to partner the project in the coming year. The company recently began work on a programme to address ETEC (enterotoxigeneic E coli), which is the primary cause of TD around the world.
In December 2005, ACE BioSciences announced a collaborative
agreement with the Aeras Global TB Vaccine Foundation whereby ACE
BioSciences will support the characterization of second-generation
BCG-based tuberculosis (TB) vaccines under development by Aeras. In
November 2005, ACE BioSciences and the Dutch bi
'"/>
Related medicine technology :
1. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
2. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
6. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
7. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
8. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
9. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
10. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
11. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |